Of late, targeted protein degradation (TPD) has surfaced as a novel and innovative chemical tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates complete removal of the protein molecules from within or outside the cell. While the pioneering Proteolysis-Targeting Chimera (PROTAC) technology and molecular glues hijack the ubiquitin-proteasome system, newer modalities co-opt autophagy or the endo-lysosomal pathway. Using this mechanism, TPD is posited to largely expand the druggable space far beyond small-molecule inhibitors. In this review, we discuss the major advances in TPD, highlight our current understanding, and explore outstanding questions in the field. Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Shanique B Alabi, Craig M Crews. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. The Journal of biological chemistry. 2021 Jan-Jun;296:100647
PMID: 33839157
View Full Text